A Phase 3 interventional study of Non-Biologic DMARDs and Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 20 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-19.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 36th largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 79th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 66th largest by enrollment of the 141 interventional ones that give a count, is one of 10 that started in 2014, is one of 85 in phase 3, and was the 176th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multi-center, open-label single arm Phase IIIb study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab administered as monotherapy and/or in combination with methotrexate or other non-biologic disease modifying antirheumatic drugs (DMARDs) in participants with rheumatoid arthritis (RA) with an inadequate response to non-biologic DMARDs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a weekly SC injection of tocilizumab 162 milligrams (mg) as monotherapy or in combination with methotrexate or other non-biologic DMARDs for 24 weeks.
Drug: Non-Biologic DMARDs · Drug: Tocilizumab · Drug: Methotrexate
Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
Also known as: RoActemra, Actemra
Methotrexate will be administered per investigator's discretion.
Percentage of Participants With Adverse Events
An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Adverse events included serious as well as non-serious adverse events.
Time frame: Baseline up to Week 32
Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal
DAS28 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, erythrocyte sedimentation rate (ESR; millimeters per hour \[mm/hour\]), and patient's global assessment of disease activity (measured on a 0 to 100 mm Visual Analog Scale \[VAS\] where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR less than or equal to (≤) 3.2 implied low disease activity and greater than (\>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-ESR less than (\<) 2.6 implied clinical remission.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Percentage of Participants Achieving an American College of Rheumatology Criteria 20 (ACR20) Response
A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or ESR).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Percentage of Participants Achieving an ACR50 Response
A participant had an ACR50 response if there was at least a 50% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Percentage of Participants Achieving an ACR70 Response
A participant had an ACR70 response if there was at least a 70% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Percentage of Participants Achieving an ACR90 Response
A participant had an ACR90 response if there was at least a 90% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Percentage of Participants With European League Against Rheumatism (EULAR) Response (Good, Moderate or No Response) Based on DAS28-ESR
DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (VAS: 0 mm=no disease activity to 100 mm=maximum disease activity). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. The DAS28-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1. Participants with change from baseline \>0.6 to ≤1.2 with a DAS28 score \>5.1, or any score with change from baseline ≤0.6, were assessed as non-responders.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal
The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician global assessment of disease activity assessed on 0-10 centimeter (cm) VAS (0 cm= no disease activity and 10 cm= worst disease activity), and CRP in milligrams per liter (mg/L). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity .
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 16, 20, 24, and Early Withdrawal
The CDAI is the numerical sum of four outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician's global assessment of disease activity assessed on 0-10 cm VAS (0 cm= no disease activity and 10 cm= worst disease activity). CDAI total score = 0-76. CDAI \<= 2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Change From Baseline in Total TJC at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal
Number of tender joints was determined by examining 28 joints for TJC28 and 68 joints for TJC68, and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28 for a TJC28 and 68 for a TJC68. A reduction in number of tender joints compared to baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Change From Baseline in Total SJC at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal
Number of swollen joints was determined by examination of 28 joints for SJC28 and 66 joints for SJC66 and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28 for a SJC28 and 66 for a SJC66. A reduction in number of swollen joints compared to baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Percentage of Participants With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Dose Reductions or Discontinuation Categorized by Reasons
Results are reported for percentage of participants who had NSAIDs dose reductions or discontinuation by reasons for dose reductions or discontinuation (unknown reasons, safety reasons, other reasons, lack of efficacy, and discomfort).
Time frame: From Week 16 and before Week 20; From Week 20 and before Week 24
Percentage of Participants With Corticosteroid Dose Reductions or Discontinuation Categorized by Reasons
Results are reported for percentage of participants who had corticosteroid dose reductions or discontinuation by reasons for dose reductions or discontinuation (unknown reasons, safety reasons, other reasons, lack of efficacy, and discomfort).
Time frame: From Week 16 and before Week 20; From Week 20 and before Week 24
Time to Discontinuation or First Dose Reduction of Corticosteroids or NSAIDs
Time to discontinuation or first dose reduction of corticosteroids or NSAIDs (weeks) = (Date of the first dose reduction or end date of corticosteroids or NSAIDs treatment - date of first drug intake of this study) + 1. Time to discontinuation or first dose reduction was based on the first occurring event (corticosteroid discontinuation or corticosteroid first dose reduction or NSAIDs discontinuation or NSAIDs first dose reduction, whichever occurred first).
Time frame: Baseline up to Week 32
Percentage of Participants With Anti-Tocilizumab Antibodies
Time frame: Baseline, Weeks 12 and 24, early withdrawal (up to Week 24), follow-up visit (8 weeks after last dose of tocilizumab, up to 32 weeks)
Serum Levels of Tocilizumab
Time frame: Baseline, Weeks 12 and 24, Early Withdrawal (up to Week 24), Follow-up Visit (8 weeks after last dose of tocilizumab, up to 32 weeks)
Serum Levels of Soluble Interleukin-6 Receptors (sIL-6Rs)
Time frame: Baseline, Weeks 12 and 24, Early Withdrawal (up to Week 24), Follow-up Visit (8 weeks after last dose of tocilizumab, up to 32 weeks)
Patient Global Assessment of Disease Activity VAS Scores
Patient global assessment of disease activity was measured on a 0 to 100 mm horizontal VAS where 0 mm=no disease activity and 100 mm=maximum disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and Early withdrawal (up to Week 24)
Patient Pain VAS Scores
This assessment represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS where 0 mm= no pain to 100 mm= unbearable pain.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and Early withdrawal (up to Week 24)
Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)
Percentage of Participants Compliant to Tocilizumab Treatment as Measured by Diary Cards and Return Records
A diary card was provided to participants to record home injections. Participants were asked to return all empty drug supply boxes, unused pre-filled syringe, and diary cards to the clinic at each visit as a measure of drug accountability and participant compliance. A participant was considered compliant if the participant correctly administered all scheduled doses of SC tocilizumab during the assessment period.
Time frame: Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
The FACIT-F score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)
| Milestone | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Started | 150 |
| Completed | 133 |
| Not completed | 17 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Physician decision | 2 |
| Withdrew: Participant/legal guardian decision | 1 |
| Withdrew: Other | 5 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Adverse event | 7 |
An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Adverse events included serious as well as non-serious adverse events.
| percentage of participants | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Percentage of Participants With Adverse Events | 91.3 |
DAS28 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, erythrocyte sedimentation rate (ESR; millimeters per hour \[mm/hour\]), and patient's global assessment of disease activity (measured on a 0 to 100 mm Visual Analog Scale \[VAS\] where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR less than or equal to (≤) 3.2 implied low disease activity and greater than (\>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-ESR less than (\<) 2.6 implied clinical remission.
| units on a scale | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Baseline (n=150) | 4.8 ± 1.3 |
| Change at Week 2 (n=148) | 1.337 ± 0.989 |
| Change at Week 4 (n=144) | 2.037 ± 0.991 |
| Change at Week 8 (n=136) | 2.635 ± 1.098 |
| Change at Week 12 (n=133) | 2.908 ± 1.135 |
| Change at Week 16 (n=128) | 3.014 ± 1.240 |
| Change at Week 20 (n=122) | 3.169 ± 1.170 |
| Change at Week 24 (n=121) | 3.232 ± 1.247 |
| Change at early withdrawal visit (n=27) | 1.653 ± 1.562 |
A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or ESR).
| percentage of participants | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Week 2 (n=148) | 20.3 ± 0.989 |
| Week 4 (n=144) | 40.3 ± 0.991 |
| Week 8 (n=136) | 58.1 ± 1.098 |
| Week 12 (n=133) | 69.9 ± 1.135 |
| Week 16 (n=130) | 71.5 ± 1.240 |
| Week 20 (n=123) | 78.9 ± 1.170 |
| Week 24 (n=121) | 82.6 ± 1.247 |
| Early withdrawal visit (n=27) | 37.0 ± 1.562 |
A participant had an ACR50 response if there was at least a 50% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).
| percentage of participants | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Week 2 (n=148) | 6.1 ± 0.989 |
| Week 4 (n=144) | 18.1 ± 0.991 |
| Week 8 (n=136) | 33.1 ± 1.098 |
| Week 12 (n=133) | 43.6 ± 1.135 |
| Week 16 (n=130) | 52.3 ± 1.240 |
| Week 20 (n=123) | 54.5 ± 1.170 |
| Week 24 (n=121) | 62.0 ± 1.247 |
| Early withdrawal visit (n=27) | 18.5 ± 1.562 |
A participant had an ACR70 response if there was at least a 70% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).
| percentage of participants | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Week 2 (n=148) | 1.4 ± 0.989 |
| Week 4 (n=144) | 6.9 ± 0.991 |
| Week 8 (n=136) | 14.0 ± 1.098 |
| Week 12 (n=133) | 21.1 ± 1.135 |
| Week 16 (n=130) | 29.2 ± 1.240 |
| Week 20 (n=123) | 38.2 ± 1.170 |
| Week 24 (n=121) | 35.5 ± 1.247 |
| Early withdrawal visit (n=27) | 14.8 ± 1.562 |
A participant had an ACR90 response if there was at least a 90% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).
| percentage of participants | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Week 2 (n=148) | 0.0 ± 0.989 |
| Week 4 (n=144) | 1.4 ± 0.991 |
| Week 8 (n=136) | 2.9 ± 1.098 |
| Week 12 (n=133) | 6.8 ± 1.135 |
| Week 16 (n=130) | 9.2 ± 1.240 |
| Week 20 (n=123) | 11.4 ± 1.170 |
| Week 24 (n=121) | 15.7 ± 1.247 |
| Early withdrawal visit (n=27) | 3.7 ± 1.562 |
DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (VAS: 0 mm=no disease activity to 100 mm=maximum disease activity). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. The DAS28-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1. Participants with change from baseline \>0.6 to ≤1.2 with a DAS28 score \>5.1, or any score with change from baseline ≤0.6, were assessed as non-responders.
| percentage of participants | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Week 2: Good response (n=148) | 34.5 ± 0.989 |
| Week 2: Moderate response (n=148) | 41.9 ± 0.991 |
| Week 2: No response (n=148) | 23.6 ± 1.098 |
| Week 4: Good response (n=144) | 59.7 ± 1.135 |
| Week 4: Moderate response (n=144) | 34.0 ± 1.240 |
| Week 4: No response (n=144) | 6.3 ± 1.170 |
| Week 8: Good response (n=136) | 78.7 ± 1.247 |
| Week 8: Moderate response (n=136) | 17.6 ± 1.562 |
| Week 8: No response (n=136) | 3.7 |
| Week 12: Good response (n=133) | 85.0 |
| Week 12: Moderate response (n=133) | 12.0 |
| Week 12: No response (n=133) | 3.0 |
| Week 16: Good response (n=128) | 89.1 |
| Week 16: Moderate response (n=128) | 7.0 |
| Week 16: No response (n=128) | 3.9 |
| Week 20: Good response (n=122) | 91.8 |
| Week 20: Moderate response (n=122) | 5.7 |
| Week 20: No response (n=122) | 2.5 |
| Week 24: Good response (n=121) | 92.6 |
| Week 24: Moderate response (n=121) | 5.0 |
| Week 24: No response (n=121) | 2.5 |
| Early withdrawal visit: Good response (n=27) | 44.4 |
| Early withdrawal visit: Moderate response (n=27) | 29.6 |
| Early withdrawal visit: No response (n=27) | 25.9 |
The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician global assessment of disease activity assessed on 0-10 centimeter (cm) VAS (0 cm= no disease activity and 10 cm= worst disease activity), and CRP in milligrams per liter (mg/L). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity .
| units on a scale | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Baseline (n=145) | 26.03 ± 12.55 |
| Change at Week 2 (n=97) | -6.2 ± 7.4 |
| Change at Week 4 (n=78) | -11.3 ± 8.0 |
| Change at Week 8 (n=64) | -14.4 ± 9.2 |
| Change at Week 12 (n=63) | -17.2 ± 10.8 |
| Change at Week 16 (n=67) | -18.5 ± 11.1 |
| Change at Week 20 (n=57) | -19.7 ± 11.2 |
| Change at Week 24 (n=56) | -19.9 ± 11.8 |
| Change at early withdrawal visit (n=18) | -8.0 ± 10.7 |
The CDAI is the numerical sum of four outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician's global assessment of disease activity assessed on 0-10 cm VAS (0 cm= no disease activity and 10 cm= worst disease activity). CDAI total score = 0-76. CDAI \<= 2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.
| units on a scale | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Baseline (n=150) | 24.32 ± 11.84 |
| Change at Week 2 (n=148) | -4.7 ± 7.3 |
| Change at Week 4 (n=144) | -9.4 ± 7.2 |
| Change at Week 8 (n=135) | -13.4 ± 8.7 |
| Change at Week 12 (n=132) | -15.4 ± 9.2 |
| Change at Week 16 (n=129) | -16.7 ± 10.1 |
| Change at Week 20 (n=122) | -17.8 ± 10.2 |
| Change at Week 24 (n=121) | -18.3 ± 11.1 |
| Change at early withdrawal visit (n=27) | -6.4 ± 10.3 |
Number of tender joints was determined by examining 28 joints for TJC28 and 68 joints for TJC68, and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28 for a TJC28 and 68 for a TJC68. A reduction in number of tender joints compared to baseline indicates improvement.
| tender joints | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| TJC28: Baseline (n=150) | 7.7 ± 6.5 |
| TJC28: Change at Week 2 (n=148) | -1.38 ± 3.71 |
| TJC28: Change at Week 4 (n=144) | -2.94 ± 3.89 |
| TJC28: Change at Week 8 (n=136) | -4.33 ± 4.82 |
| TJC28: Change at Week 12 (n=133) | -4.68 ± 5.05 |
| TJC28: Change at Week 16 (n=130) | -5.36 ± 5.55 |
| TJC28: Change at Week 20 (n=123) | -5.79 ± 5.24 |
| TJC28: Change at Week 24 (n=121) | -5.96 ± 5.67 |
| TJC28: Change at early withdrawal visit (n=27) | -1.07 ± 4.59 |
| TJC68: Baseline (n=150) | 13.2 ± 10.0 |
| TJC68: Change at Week 2 (n=148) | -2.40 ± 5.84 |
| TJC68: Change at Week 4 (n=144) | -5.15 ± 6.25 |
| TJC68: Change at Week 8 (n=136) | -7.19 ± 7.57 |
| TJC68: Change at Week 12 (n=133) | -7.98 ± 8.46 |
| TJC68: Change at Week 16 (n=130) | -9.45 ± 9.07 |
| TJC68: Change at Week 20 (n=123) | -9.86 ± 9.04 |
| TJC68: Change at Week 24 (n=121) | -10.02 ± 8.94 |
| TJC68: Change at early withdrawal visit (n=27) | -1.93 ± 8.53 |
Number of swollen joints was determined by examination of 28 joints for SJC28 and 66 joints for SJC66 and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28 for a SJC28 and 66 for a SJC66. A reduction in number of swollen joints compared to baseline indicates improvement.
| swollen joints | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| SJC28: Baseline (n=150) | 6.2 ± 5.4 |
| SJC28: Change at Week 2 (n=148) | -1.18 ± 3.04 |
| SJC28: Change at Week 4 (n=144) | -2.44 ± 3.33 |
| SJC28: Change at Week 8 (n=136) | -3.62 ± 3.86 |
| SJC28: Change at Week 12 (n=133) | -4.24 ± 4.17 |
| SJC28: Change at Week 16 (n=130) | -4.61 ± 4.14 |
| SJC28: Change at Week 20 (n=123) | -4.92 ± 4.24 |
| SJC28: Change at Week 24 (n=121) | -5.23 ± 4.63 |
| SJC28: Change at early withdrawal visit (n=27) | -1.33 ± 4.18 |
| SJC66: Baseline (n=150) | 9.1 ± 7.3 |
| SJC66: Change at Week 2 (n=148) | -1.84 ± 4.16 |
| SJC66: Change at Week 4 (n=144) | -3.94 ± 4.35 |
| SJC66: Change at Week 8 (n=136) | -5.61 ± 4.74 |
| SJC66: Change at Week 12 (n=133) | -6.50 ± 5.79 |
| SJC66: Change at Week 16 (n=130) | -6.78 ± 5.95 |
| SJC66: Change at Week 20 (n=123) | -7.52 ± 6.44 |
| SJC66: Change at Week 24 (n=121) | -7.80 ± 6.86 |
| SJC66: Change at early withdrawal visit (n=27) | -2.33 ± 4.89 |
Results are reported for percentage of participants who had NSAIDs dose reductions or discontinuation by reasons for dose reductions or discontinuation (unknown reasons, safety reasons, other reasons, lack of efficacy, and discomfort).
| percentage of participants | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Unknown reasons (Week 16 to Week 20) | 0.0 |
| Safety reasons (Week 16 to Week 20) | 0.7 |
| Other reasons (Week 16 to Week 20) | 0.7 |
| Lack of efficacy (Week 16 to Week 20) | 0.0 |
| Discomfort (Week 16 to Week 20) | 0.0 |
| Unknown reasons (Week 20 to Week 24) | 0.0 |
| Safety reasons (Week 20 to Week 24) | 0.0 |
| Other reasons (Week 20 to Week 24) | 0.0 |
| Lack of efficacy (Week 20 to Week 24) | 0.0 |
| Discomfort (Week 20 to Week 24) | 0.0 |
Results are reported for percentage of participants who had corticosteroid dose reductions or discontinuation by reasons for dose reductions or discontinuation (unknown reasons, safety reasons, other reasons, lack of efficacy, and discomfort).
| percentage of participants | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Unknown reasons (Week 16 to Week 20) | 0.0 |
| Safety reasons (Week 16 to Week 20) | 1.3 |
| Other reasons (Week 16 to Week 20) | 0.7 |
| Lack of efficacy (Week 16 to Week 20) | 0.0 |
| Discomfort (Week 16 to Week 20) | 0.0 |
| Unknown reasons (Week 20 to Week 24) | 0.0 |
| Safety reasons (Week 20 to Week 24) | 0.0 |
| Other reasons (Week 20 to Week 24) | 1.3 |
| Lack of efficacy (Week 20 to Week 24) | 0.7 |
| Discomfort (Week 20 to Week 24) | 0.0 |
Time to discontinuation or first dose reduction of corticosteroids or NSAIDs (weeks) = (Date of the first dose reduction or end date of corticosteroids or NSAIDs treatment - date of first drug intake of this study) + 1. Time to discontinuation or first dose reduction was based on the first occurring event (corticosteroid discontinuation or corticosteroid first dose reduction or NSAIDs discontinuation or NSAIDs first dose reduction, whichever occurred first).
| weeks | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Time to Discontinuation or First Dose Reduction of Corticosteroids or NSAIDs | 25.3 (25.0 to 28.0) |
| percentage of participants | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Baseline (n=147) | 6.1 ± 0.5906 |
| Week 12 (n=5) | 40.0 ± 0.5734 |
| Week 24 (n=121) | 7.4 ± 0.5587 |
| Early withdrawal (n=22) | 9.1 ± 0.5330 |
| Follow-up visit (n=26) | 11.5 ± 0.5682 |
| micrograms per milliliter (mcg/mL) | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Baseline (n=4) | 0.5 ± 0.3 |
| Week 12 (n=123) | 42.3 ± 25.2 |
| Week 24 (n=112) | 46.5 ± 29.2 |
| Early withdrawal (n=17) | 16.8 ± 19.3 |
| Follow-up visit (n=3) | 60.9 ± 29.7 |
| nanograms per milliliter (ng/mL) | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Baseline (n=139) | 38.3 ± 10.4 |
| Week 12 (n=126) | 516.6 ± 137.7 |
| Week 24 (n=115) | 536.5 ± 161.6 |
| Early withdrawal (n=21) | 380.4 ± 215.2 |
| Follow-up visit (n=26) | 117.5 ± 194.3 |
Patient global assessment of disease activity was measured on a 0 to 100 mm horizontal VAS where 0 mm=no disease activity and 100 mm=maximum disease activity.
| mm | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Baseline (n=150) | 54.8 ± 22.3 |
| Week 2 (n=148) | 43.6 ± 23.0 |
| Week 4 (n=144) | 35.5 ± 23.0 |
| Week 8 (n=136) | 27.2 ± 21.8 |
| Week 12 (n=133) | 22.2 ± 20.3 |
| Week 16 (n=129) | 21.3 ± 21.0 |
| Week 20 (n=123) | 19.2 ± 18.6 |
| Week 24 (n=121) | 18.8 ± 19.5 |
| Early withdrawal (n=27) | 40.4 ± 30.9 |
This assessment represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS where 0 mm= no pain to 100 mm= unbearable pain.
| mm | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Baseline (n=150) | 52.5 ± 22.1 |
| Week 2 (n=148) | 44.4 ± 21.9 |
| Week 4 (n=144) | 35.8 ± 22.3 |
| Week 8 (n=136) | 27.6 ± 21.3 |
| Week 12 (n=133) | 21.7 ± 19.0 |
| Week 16 (n=129) | 20.9 ± 20.2 |
| Week 20 (n=123) | 19.5 ± 18.0 |
| Week 24 (n=121) | 19.6 ± 18.8 |
| Early withdrawal (n=27) | 42.8 ± 30.4 |
The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do.
| units on a scale | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Baseline (n=147) | 1.2329 ± 0.5708 |
| Week 2 (n=147) | 1.0978 ± 0.5906 |
| Week 4 (n=143) | 0.9673 ± 0.5734 |
| Week 8 (n=134) | 0.8249 ± 0.5587 |
| Week 12 (n=131) | 0.7460 ± 0.5330 |
| Week 16 (n=129) | 0.6996 ± 0.5682 |
| Week 20 (n=122) | 0.6620 ± 0.5333 |
| Week 24 (n=119) | 0.6681 ± 0.5745 |
| Early withdrawal (n=27) | 1.2315 ± 0.6853 |
A diary card was provided to participants to record home injections. Participants were asked to return all empty drug supply boxes, unused pre-filled syringe, and diary cards to the clinic at each visit as a measure of drug accountability and participant compliance. A participant was considered compliant if the participant correctly administered all scheduled doses of SC tocilizumab during the assessment period.
| percentage of participants | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Week 2 (n=148) | 90.5 ± 0.5906 |
| Week 4 (n=144) | 95.8 ± 0.5734 |
| Week 8 (n=136) | 91.9 ± 0.5587 |
| Week 12 (n=133) | 97.7 ± 0.5330 |
| Week 16 (n=130) | 93.8 ± 0.5682 |
| Week 20 (n=123) | 95.1 ± 0.5333 |
| Week 24 (n=121) | 92.6 ± 0.5745 |
| Early withdrawal (n=27) | 88.9 ± 0.6853 |
The FACIT-F score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
| units on a scale | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Baseline (n=133) | 29.84 ± 9.43 |
| Week 2 (n=134) | 33.07 ± 9.34 |
| Week 4 (n=133) | 35.10 ± 10.37 |
| Week 8 (n=126) | 37.34 ± 9.25 |
| Week 12 (n=126) | 37.89 ± 8.52 |
| Week 16 (n=122) | 37.93 ± 9.11 |
| Week 20 (n=118) | 39.65 ± 8.87 |
| Week 24 (n=114) | 39.93 ± 8.65 |
| Early withdrawal (n=27) | 33.48 ± 12.06 |
Collected over Baseline up to Week 32. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | — | 14/150 (9.3%) | 77/150 (51.3%) |
| Event | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| AppendicitisInfections and infestations | 1/150 |
| Arthritis bacterialInfections and infestations | 1/150 |
| Skin infectionInfections and infestations | 1/150 |
| Scapula fractureInjury, poisoning and procedural complications | 1/150 |
| Tibia fractureInjury, poisoning and procedural complications | 1/150 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/150 |
| Joint range of motion decreasedMusculoskeletal and connective tissue disorders | 1/150 |
| B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/150 |
| Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/150 |
| PsoriasisSkin and subcutaneous tissue disorders | 1/150 |
| Event | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| NasopharyngitisInfections and infestations | 35/150 |
| NauseaGastrointestinal disorders | 18/150 |
| FatigueGeneral disorders | 18/150 |
| DizzinessNervous system disorders | 11/150 |
| DiarrhoeaGastrointestinal disorders | 9/150 |
| RashSkin and subcutaneous tissue disorders | 8/150 |
| LeukopeniaBlood and lymphatic system disorders | 8/150 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 8/150 |
Full Analysis Set (FAS) population included all participants who received at least one dose of SC tocilizumab.
| Age, Continuous(years) | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Mean | 55.85 ± 11.20 |
| Sex: Female, Male(Participants) | Tocilizumab Alone or in Combination With Methotrexate or DMARD |
|---|---|
| Female | 110 |
| Male | 40 |
Ran from Jan 2014 to primary completion in May 2016, 27 months.
Results were first posted in Jun 2017, 1 year after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 27 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tocilizumab · Methotrexate